59 results
8-K
EX-3.1
ASRT
Assertio Holdings Inc
30 May 24
Departure of Directors or Certain Officers
4:32pm
of Section 8 of the Clayton Antitrust Act of 1914) or maintain, increase or decrease the voting power of the stockholder, beneficial owner or control person … equity interests in any principal competitor of the Corporation (as defined for the purposes of Section 8 of the Clayton Antitrust Act of 1914) held
8-K
EX-99.1
ASRT
Assertio Holdings Inc
6 May 24
Assertio Reports First Quarter 2024 Financial Results
4:01pm
suppositories, antitrust litigation, opioid-related government investigations and opioid-related litigation, as well as Spectrum’s legacy shareholder and other
8-K/A
ASRT
Assertio Holdings Inc
12 Mar 24
Results of Operations and Financial Condition
5:01pm
to the Spectrum Merger and/or the recent approval and launch of generic indomethacin suppositories, antitrust litigation, opioid-related government
8-K
EX-99.1
luug8o5tc
11 Mar 24
Assertio Reports Fourth Quarter and Full Year 2023 Financial Results
5:07pm
8-K
EX-99
055t mpwm
8 Nov 23
Assertio Reports Third Quarter 2023 Financial Results
4:03pm
8-K
EX-99.1
npn91dvbhtlyd
3 Aug 23
Assertio Reports Second Quarter 2023 Financial Results, Closes Spectrum Acquisition
4:08pm
424B3
967lpyssgjtrxlrr
15 Jun 23
Prospectus supplement
4:23pm
425
7d3vz8h1eizxk4hdz2
9 May 23
Business combination disclosure
5:10pm
425
EX-99.1
fnrpxv76
9 May 23
Business combination disclosure
7:16am
8-K
EX-99.1
kfp5csy
9 May 23
Assertio Reports First Quarter 2023 Financial Results, Raises Full Year 2023 Outlook
7:15am
425
7dewh0y3fw
25 Apr 23
Business combination disclosure
4:39pm